血小板活化在慢性阻塞性肺疾病合并肺动脉高压中的作用研究
The Role of Platelet Activation in Chronic Obstructive Pulmonary Disease Complicated with Pulmonary Hypertension
DOI: 10.12677/ACM.2022.1291268, PDF,   
作者: 王凯丽：青海大学医学院，青海 西宁；白振忠*：青海大学附属医院，青海 西宁
关键词: COPD；肺动脉高压；血小板活化；COPD； Pulmonary Hypertension； Platelet Activation
摘要: 慢性阻塞性肺疾病是一种以气流持续存在受限的慢性呼吸系统疾病，存在气道受限不可逆、高患病率、高死亡率等特点，是我国常见的呼吸系统疾病。当慢性阻塞性肺疾病呈进行性发展时，往往伴随肺动脉高压的形成，这严重的危害了患者的生命健康。近年来有研究发现，体内血小板的活化可影响慢性阻塞性肺疾病合并肺动脉高压的发生发展，例如血小板活化因子PAF、PF4、CD62P，影响血小板活化的因素等。本文就血小板活化对慢性阻塞性肺疾病合并肺动脉高压的影响作一综述，为临床治疗提供新思路。
Abstract: Chronic obstructive pulmonary disease (COPD) is a chronic respiratory disease characterized by persistent airflow limitation. It has the characteristics of irreversible airway limitation, high mor-bidity and high mortality. It is a common respiratory disease in my country. When chronic obstruc-tive pulmonary disease develops progressively, it is often accompanied by the formation of pulmo-nary hypertension, which seriously endangers the life and health of patients. In recent years, stud-ies have found that platelet activation in vivo can affect the occurrence and development of chronic obstructive pulmonary disease complicated with pulmonary hypertension, such as platelet activat-ing factors PAF, PF4, CD62P, and factors affecting platelet activation. This article reviews the effect of platelet activation on chronic obstructive pulmonary disease complicated with pulmonary hyper-tension, and provides new ideas for clinical treatment.
文章引用：王凯丽, 白振忠. 血小板活化在慢性阻塞性肺疾病合并肺动脉高压中的作用研究[J]. 临床医学进展, 2022, 12(9): 8786-8790. https://doi.org/10.12677/ACM.2022.1291268

参考文献

[1] Christenson, S.A., Smith, B.M., Bafadhel, M., et al. (2022) Chronic Obstructive Pulmonary Disease. The Lancet, 399, 2227-2242. [Google Scholar] [CrossRef] 
[2] 胡文, 蒋永亮. 2019年全球慢性阻塞性肺病倡议报告中的中国文献[J]. 中国实用内科杂志, 2019, 39(10): 918-922.
[3] 沈奕播, 聂洪玉, 李琦. 慢性阻塞性肺疾病合并肺动脉高压患者的临床特征与危险因素分析[J]. 中华老年多器官疾病杂志, 2018, 17(5): 371-375.
[4] 王同生, 毛毅敏, 孙瑜霞, 等. 慢性阻塞性肺疾病合并肺动脉高压的临床特征及高危因素[J]. 中华内科杂志, 2015, 54(12): 1037-1040.
[5] 张书茵, 姜俭, 邵荣海, 等. 血小板活化水平与慢性阻塞性肺疾病急性发作相关肺动脉高压的临床研究[J]. 中国急救医学, 2022, 42(2): 142-148.
[6] Estevez, B. and Du, X. (2017) New Concepts and Mechanisms of Platelet Activation Signaling. Physiology (Bethesda), 32, 162-177. [Google Scholar] [CrossRef] [PubMed]
[7] Nunez, A., Marras, V., Harlander, M., et al. (2020) Association between Routine Blood Biomarkers and Clinical Phenotypes and Exacerbations in Chronic Obstructive Pulmonary Dis-ease. International Journal of Chronic Obstructive Pulmonary Disease, 15, 681-690. [Google Scholar] [CrossRef] 
[8] 吴挺实, 梁勇, 陈钰. 慢性阻塞性肺疾病急性加重期患者的血小板活化及氧化应激变化研究[J]. 检验医学与临床, 2016, 13(16): 2384-2386.
[9] Chakravarty, V., Anandi, L., Ashiq, K.A., et al. (2021) Prolonged Exposure to Platelet Activating Factor Transforms Breast Epithelial Cells. Frontiers in Genetics, 12, Article ID: 634938. [Google Scholar] [CrossRef] [PubMed]
[10] de Castro, S.H., Faria, N.H. and Gomes, M.B. (2007) Platelet-Activating Factor Acetylhydrolase (PAF-AH) Activity in Patients with Type 1 Diabe-tes Mellitus. Arquivos Brasileiros de Cardiologia, 88, 179-184. [Google Scholar] [CrossRef] 
[11] Nazy, I., Elliott, T.D. and Arnold, D.M. (2020) Platelet Factor 4 Inhibits ADAMTS13 Activity and Regulates the Multimeric Distribution of Von Willebrand Factor. British Journal of Haematology, 190, 594-598. [Google Scholar] [CrossRef] [PubMed]
[12] 耑冰, 李萍, 赵霞, 等. 血PAF、PAF-AH在COPD相关肺动脉高压炎性机制中的作用研究[J]. 宁夏医学杂志, 2015, 37(4): 292-295.
[13] 高笑宇, 刘柯含, 云春梅. 血小板活化因子在慢阻肺合并肺动脉高压中的诊断价值[J]. 内蒙古医科大学学报, 2022, 44(1): 15-19.
[14] Walker, E.K., Nauman, E.A., Allain, J.P., et al. (2015) An in Vitro Model for Preclinical Testing of Thrombogenicity of Resorbable Metallic Stents. Journal of Biomedical Materials Research Part A, 103, 2118-2125. [Google Scholar] [CrossRef] [PubMed]
[15] Lane, D.A., Ireland, H., Wolff, S., et al. (1984) Detection of Enhanced in Vivo Platelet Alpha-Granule Release in Different Patient Groups—Comparison of Beta-Thromboglobulin, Platelet Factor 4 and Thrombospondin Assays. Thrombosis and Haemostasis, 52, 183-187. [Google Scholar] [CrossRef] 
[16] 吴京凤, 杨媛华, 庞宝森. 慢性阻塞性肺疾病急性加重患者血浆血小板因子4及β凝血球蛋白水平的变化及其意义[J]. 中华医学杂志, 2013(18): 1378-1382.
[17] Mallah, H., Ball, S., Sekhon, J., et al. (2020) Platelets in Chronic Obstructive Pulmonary Disease: An Update on Pathophysiology and Implications for Antiplatelet Therapy. Respiratory Medicine, 171, Article ID: 106098. [Google Scholar] [CrossRef] [PubMed]
[18] Shen, L., Yang, T., Xia, K., et al. (2020) P-selectin (CD62P) and Soluble TREM-Like Transcript-1 (sTLT-1) Are Associated with Coronary Artery Disease: A Case Control Study. BMC Cardiovascular Disorders, 20, Article No. 387. [Google Scholar] [CrossRef] [PubMed]
[19] 虞冬晴, 车路. 急性缺血性脑梗死患者CD62p、CD63及血小板活化因子表达水平与临床预后的关系[J]. 实用临床医药杂志, 2021, 25(19): 36-38.
[20] 王志刚, 郑红艳, 林学军. 血浆内皮素-1和血小板p-选择素在慢性阻塞性肺疾病中的检测及临床意义[J]. 中国当代医药, 2020, 27(22): 4-7.
[21] 王道峰, 何世贵, 闻寅, 等. 慢性阻塞性肺疾病急性加重期患者的血小板活化程度分析[J]. 中国临床医学, 2015, 22(6): 746-749.
[22] Korniluk, A., Koper-Lenkiewicz, O.M., Kaminska, J., et al. (2019) Mean Platelet Volume (MPV): New Perspectives for an Old Marker in the Course and Prognosis of Inflammatory Conditions. Mediators of Inflammation, 2019, Article ID: 9213074. [Google Scholar] [CrossRef] [PubMed]
[23] Feng, Y., Yin, H., Mai, G., et al. (2011) Elevated Serum Levels of CCL17 Correlate with Increased Peripheral Blood Platelet Count in Patients with Active Tuberculosis in China. Clinical and Vaccine Immunology, 18, 629-632. [Google Scholar] [CrossRef] 
[24] Dixit, D., Bridgeman, M.B. andrews, L.B., et al. (2015) Acute Exacer-bations of Chronic Obstructive Pulmonary Disease: Diagnosis, Management, and Prevention in Critically Ill Patients. Pharmacotherapy, 35, 631-648. [Google Scholar] [CrossRef] [PubMed]
[25] Mohamed, M.F., Ali, A., Abbas, A., et al. (2019) Mean Platelet Volume as a Predictor of Pulmonary Hypertension in Patients with Stable COPD. International Journal of Chronic Obstructive Pulmonary Disease, 14, 1099-1108. [Google Scholar] [CrossRef] 
[26] 刘会敏. 血小板体积、血小板分布宽度及红细胞分布宽度与早发冠心病的关系[J]. 医药论坛杂志, 2021, 42(2): 59-61.
[27] Bialas, A.J., Pedone, C., Piotrowski, W.J., et al. (2017) Platelet Distribution Width as a Prognostic Factor in Patients with COPD-Pilot Study. International Journal of Chronic Obstructive Pulmonary Disease, 12, 2261-2267. [Google Scholar] [CrossRef] 
[28] 韩静, 刘晓宇, 翁军, 等. PDW、BNP及LDH在COPD合并PH患者中的变化及其临床意义[J]. 分子诊断与治疗杂志, 2021, 13(8): 1268-1271.
[29] Bai, Y. and Tao, X.N. (2020) Mean Platelet Volume Combined Red Cell Distribution Width as Biomarker of Chronic Obstructive Pulmonary Disease with Pulmonary Heart Disease. The Clinical Respiratory Journal, 14, 1122-1130. [Google Scholar] [CrossRef] [PubMed]

为你推荐